Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04878627 · ClinicalTrials.gov registry record · Early Phase 1
Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa
A Early Phase 1 study of Anorexia Nervosa, sponsored by University of California, San Diego.
- Active
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04878627: Active Early Phase 1 study of Anorexia Nervosa, sponsored by University of California, San Diego.
NCT04878627 is a Early Phase 1 study of Anorexia Nervosa that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 40 participants, below the 949-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04878627, a Early Phase 1 study of Anorexia Nervosa, is active but no longer recruiting, sponsored by University of California, San Diego.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
No studies of cannabidiol (CBD) have focused on Anorexia Nervosa (AN). Dose, side effects, tolerability, acceptability of pure CBD in AN must be established. The current study is an important first step in the investigation of CBD for AN. Cannabis products have been recently legalized in many states, and CBD in particular has been shown to reduce anxiety. Therefore, CBD may represent a promising new treatment for AN. The endocannabinoid system is involved in the regulation of functions relevant to eating disorders. Furthermore, data suggest that eating disorders are associated with alterations of the endocannabinoid system. Prior attempts to target the endocannabinoid system in AN have focused on CB1 receptor agonists that can increase anxiety. Moreover, CBD may be particularly beneficial in decreasing anxiety in AN via its action at serotonin receptors. Lastly, the impact of CBD on eating behavior and weight in AN must be determined. The current study seeks to explore these hypotheses using the aims in the following section.
Primary Outcome
The Committee of Clinical Investigations (UKU) scale is used to rate psychiatric (e.g., depression, failing memory, concentration difficulty), neurological (e.g., rigidity, tremor, epileptic seizure), and autonomic (e.g., nausea, diarrhea, tachycardia) side effects, plus others. Higher scores indicate more side effects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Study Locations (1)
California
- University of California San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
What the registry record for NCT04878627 still lists
NCT04878627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 949-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Anorexia Nervosa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04878627 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04878627 about?
NCT04878627 is a clinical study titled "Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa". No studies of cannabidiol (CBD) have focused on Anorexia Nervosa (AN). Dose, side effects, tolerability, acceptability of pure CBD in AN must be established. The current study is an important first step in the investigation of CBD for AN. Cannabis products have been recently legalized in many states...
What is the current status of trial NCT04878627?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2022-01-20. Estimated completion is 2026-06.
What conditions does trial NCT04878627 study?
This clinical trial studies the following conditions: Anorexia Nervosa.
What interventions are being tested in trial NCT04878627?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT04878627?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04878627 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anorexia Nervosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04878627's enrollment target sits among peer trials
40 23rd of 43 higher than 18 of 43 other Anorexia Nervosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anorexia Nervosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Diet for Relapse Prevention in Anorexia Nervosa
RECRUITING · NA
-
Facing Eating Disorder Fears for Anorexia Nervosa
RECRUITING · NA
-
Therapeutic Ketogenic Diet in Anorexia Nervosa
RECRUITING · NA
-
Confirming the Effectiveness of Online Guided Self-Help Family-Based Treatment for Adolescent Anorexia Nervosa
RECRUITING · NA
-
Eating Disorders Genetics Initiative 2
RECRUITING
-
Incentive Processing and Learning in Anorexia Nervosa and Bulimia Nervosa
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI